Table 6.

Incidence of cardiometabolic comorbidities among Chinese girls with obesity assessed between 2008 and 2017 in Hangzhou (Zhejiang Province, China).

Girls	Aged <10 years			Aged ≥10 years
	2008–2012	2013–2017	p-Value	2008–2012	2013–2017	p-Value
N	232	276		178	275
Impaired fasting glucose	56 (24.1%)	65 (23.6%)	0.92	42 (23.6%)	78 (28.4%)	0.28
Impaired glucose tolerance	24 (10.3%)	31 (11.2%)	0.78	39 (21.9%)	56 (20.4%)	0.72
Abnormal glycaemia	73 (31.5%)	83 (30.1%)	0.77	66 (37.1%)	119 (43.3%)	0.20
Type 2 diabetes	nil	5 (1.8%)	0.07	4 (2.2%)	26 (9.5%)	0.002
Hypertension	47 (20.3%)	115 (41.7%)	<0.0001	37 (20.8%)	109 (39.6%)	<0.0001
Dyslipidaemia	84 (36.5%)	80 (29.5%)	0.10	93 (52.5%)	117 (43.8%)	0.08
Hyperuricaemia	12 (5.3%)	12 (4.5%)	0.68	15 (8.7%)	39 (14.5%)	0.08
Acanthosis nigricans	106 (48.0%)	155 (56.6%)	0.058	118 (68.2%)	223 (81.7%)	0.001
Abnormal liver function	104 (46.0%)	89 (33.2%)	0.004	88 (50.6%)	160 (59.3%)	0.08
NAFLD	84 (36.2%)	80 (29.0%)	0.09	103 (57.9%)	166 (60.4%)	0.63
Metabolic syndrome	–	–	–	74 (41.6%)	127 (46.2%)	0.38

Data are n (%). p-Values are derived from chi-square tests or Fisher’s exact tests; they correspond to comparisons in the incidence of particular comorbidity between time periods within a given age group. Statistically significant p-values (<0.05) are shown in bold.

NAFLD, non-alcoholic fatty liver disease.